EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #02692_C
人红细胞扩增的无血清培养补充物
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
StemSpan™红细胞扩增补充（100X）含有重组人细胞因子的组合，用于选择性地促进从人脐带血（CB）或骨髓（BM）样本中分离的CD34+细胞的红细胞祖细胞的扩增和分化。
当添加到无血清培养基中时，StemSpan™红细胞扩增补充剂通常促进每个输入CD34+细胞在CD34+人CB细胞启动的14天液体培养中产生数千个红细胞。请参阅data选项卡了解更多详细信息。
StemSpan™红系扩增补充（100X）用于与以下StemSpan™培养基结合使用：
•StemSpan™SFEM（目录#09600）
StemSpan™SFEM II（目录#09605）
StemSpan™-XF（目录#100-0073）
StemSpan™-ACF红系扩增培养基（目录#09860）
Contains
• Recombinant human stem cell factor (SCF)
• Recombinant human interleukin 3 (IL-3)
• Recombinant human erythropoietin (EPO)
• This product contains only recombinant proteins and synthetic components
Subtype
Supplements
Cell Type
Erythroid Cells, Hematopoietic Stem and Progenitor Cells
Species
Human
Application
Cell Culture, Differentiation, Expansion
Brand
StemSpan
Area of Interest
Stem Cell Biology, Transplantation Research
Formulation Category
Animal Component-Free, Serum-Free
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (11)
文献 (3)
Peripheral blood derived induced pluripotent stem cells (iPSCs) from a female with familial hypertrophic cardiomyopathy. Stem cell research 2017
Abstract
Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) obtained from a 62-year-old female with familial hypertrophic cardiomyopathy (HCM). PBMCs were reprogrammed to a pluripotent state following transfection with non-integrative episomal vectors carrying reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotency markers, possess trilineage differentiation potential, carry rare variants identified in DNA isolated directly from the patient's whole blood, have a normal karyotype and no longer carry episomal vectors for reprogramming. This line is a useful resource for identifying unknown genetic causes of HCM.
Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene. Stem cell research 2017
Abstract
Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) isolated from the whole blood of a 43-year-old male with hypertrophic cardiomyopathy (HCM) who carries the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7). Patient-derived PBMCs were reprogrammed using non-integrative episomal vectors containing reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotent markers, have trilineage differentiation potential, carry the pathogenic MYH7 variant p.Val698Ala, have a normal karyotype and no longer carry the episomal reprogramming vector. This line is useful for studying the link between variants in MYH7 and the pathogenesis of HCM.
Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Science translational medicine 2016 OCT
Abstract
Genetic diseases of blood cells are prime candidates for treatment through ex vivo gene editing of CD34+ hematopoietic stem/progenitor cells (HSPCs), and a variety of technologies have been proposed to treat these disorders. Sickle cell disease (SCD) is a recessive genetic disorder caused by a single-nucleotide polymorphism in the $\beta$-globin gene (HBB). Sickle hemoglobin damages erythrocytes, causing vasoocclusion, severe pain, progressive organ damage, and premature death. We optimize design and delivery parameters of a ribonucleoprotein (RNP) complex comprising Cas9 protein and unmodified single guide RNA, together with a single-stranded DNA oligonucleotide donor (ssODN), to enable efficient replacement of the SCD mutation in human HSPCs. Corrected HSPCs from SCD patients produced less sickle hemoglobin RNA and protein and correspondingly increased wild-type hemoglobin when differentiated into erythroblasts. When engrafted into immunocompromised mice, ex vivo treated human HSPCs maintain SCD gene edits throughout 16 weeks at a level likely to have clinical benefit. These results demonstrate that an accessible approach combining Cas9 RNP with an ssODN can mediate efficient HSPC genome editing, enables investigator-led exploration of gene editing reagents in primary hematopoietic stem cells, and suggests a path toward the development of new gene editing treatments for SCD and other hematopoietic diseases.
更多信息
| 种属 | Human |
|---|---|
| Contains | • Recombinant human stem cell factor (SCF) • Recombinant human interleukin 3 (IL-3) • Recombinant human erythropoietin (EPO) • This product contains only recombinant proteins and synthetic components |
| 配方类别 | Animal Component-Free, Serum-Free |
相关产品
-
StemSpan™ SFEM II用于培养和扩增造血细胞的无血清培养基
-
StemSpan™-ACF红系扩增培养基用于培养和扩增人红系细胞的无动物成分培养基
-
抗人CD71（转铁蛋白受体）抗体，克隆OKT9小鼠单克隆IgG1抗体，抗人CD71（转铁蛋白受体）
